AtriCure (ATRC) versus OraSure Technologies (OSUR) Head-To-Head Survey

AtriCure (NASDAQ: ATRC) and OraSure Technologies (NASDAQ:OSUR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Insider & Institutional Ownership

86.2% of AtriCure shares are owned by institutional investors. Comparatively, 94.5% of OraSure Technologies shares are owned by institutional investors. 11.9% of AtriCure shares are owned by insiders. Comparatively, 6.4% of OraSure Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

AtriCure has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500.


This table compares AtriCure and OraSure Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AtriCure -19.40% -20.28% -12.20%
OraSure Technologies 20.48% 14.12% 12.57%

Valuation and Earnings

This table compares AtriCure and OraSure Technologies’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AtriCure $155.11 million 4.11 -$33.33 million ($1.02) -18.14
OraSure Technologies $128.20 million 7.83 $19.72 million $0.52 31.83

OraSure Technologies has lower revenue, but higher earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for AtriCure and OraSure Technologies, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AtriCure 0 1 6 0 2.86
OraSure Technologies 0 1 4 0 2.80

AtriCure presently has a consensus target price of $25.00, suggesting a potential upside of 35.14%. OraSure Technologies has a consensus target price of $17.25, suggesting a potential upside of 4.23%. Given AtriCure’s stronger consensus rating and higher possible upside, research analysts clearly believe AtriCure is more favorable than OraSure Technologies.


OraSure Technologies beats AtriCure on 8 of the 13 factors compared between the two stocks.

AtriCure Company Profile

AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart’s left atrial appendage (LAA).

OraSure Technologies Company Profile

OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company operates in two segments: OSUR and DNAG. OSUR consists of the development, manufacture and sale of diagnostic products, specimen collection devices, and medical devices. DNAG or molecular collection systems business consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing. It also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. It sells over-the-counter (OTC) cryosurgical products to consumers in North America, Europe, Central and South America, and Australia.

Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with's FREE daily email newsletter.

Leave a Reply